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It is estimated that each HIV-positive child in South Africa costs the 
government more in terms of health and welfare expenses than it does to 
reduce mother-to-child transmission (MTCT) of HIV through the use of 
anti-retroviral regimens (where the mother continues to breast-feed).  
Programmes to reduce MTCT of HIV/AIDS are thus clearly affordable.  
Using Nevirapine (according to the HIVNET 012 Protocol) saves fewer 
lives, but is more cost-effective than using Zidovudine (CDC two-week 






South Africa has the fastest-growing AIDS epidemic in the world, and 
more HIV-positive people than any other country.  Commenting on the 
five-fold increase between 1990 and 1999 in the number of people dying at  
the age of 30, Dr. Makgoba (the head of South Africa’s Medical Research 
Council) observed that only a war would give comparable deaths amongst 
young people (cited in Van der Vliet, 2000a).        
South Africa is clearly facing a crisis of disturbing proportions.  
To make matters worse, the government’s response has been slow, 
stumbling and at times counter-productive (see Marais, 2000; Van der 
Vliet, 2001).  This is particularly evident with regard to mother-to-child 
transmission (MTCT) of HIV.  As the Mail and Guardian argued in an 
editorial on 21 July 2000: 
 
‘If our government any longer hesitates and 
prevaricates on the issue of providing anti-retrovirals to HIV-
positive pregnant women, it should not be surprised to hear 
charges of genocide directed against it.  For to fail to act right 
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now against the HIV/AIDS pandemic on the basis of best-
available science and with all the resources we can muster will 
have genocidal results.  Whether the outcome is the result of 
malevolence, of incompetence, of panic-induced denial, or of 
pig-headed obduracy among senior members of the 
government will scarcely matter.  For they will have been 
warned often enough.’ 
 
This paper discusses the economics of preventing MTCT of HIV in South 
Africa.  We do not speculate about whether the government’s failure to act 
appropriately was the result of ‘malevolence, incompetence, panic-induced 
denial or pig-headed obduracy’, but rather explore the economic concerns 
about affordability and effectiveness that may have been relevant to 
government’s decision-making on this issue.   
We begin by reviewing the different approaches taken by various 
studies to the cost-effectiveness of preventing MTCT of HIV in South 
Africa – all of which conclude that the government should have been 
allocating resources to prevent such transmission.  The question thus raised 
is why, in the face of such evidence, the Ministry of Health continues to 
maintain that a MTCT prevention programme is ‘unaffordable’.  While this 
may be a convenient excuse for inaction, it is possible that this policy 
position has arisen because existing studies of cost-effectiveness do not 
frame the argument in a way that addresses the full impact on the 
government’s budget.      
We then present an alternative way of approaching the issue of 
affordability – i.e. by comparing the costs to the health sector of two short-
course drug regimens that reduce MTCT with the costs of not intervening.  
We show that unless the government is planning to deny hospital care to 
children with HIV/AIDS (which would be unconstitutional in South 
Africa), it costs the government more to let the children contract HIV from 
their mothers, get sick and die, than it does to save them.   There is, in other 
words, no basis for the argument that the government ‘cannot afford’ a 
programme to prevent MTCT.    
There are of course various alternative treatment regimes to reduce 
MTCT that involve different drugs, in different combinations and with 
different infant-feeding regimes (see e.g. Marseilles and Kahn, 1999, Farley 
et al, 2000).  This paper considers two easy-to-administer regimes (i.e. a 
short course of AZT from the 36th week of pregnancy and three-hourly 
during labour; and a single dose of Nevirapine for the mother and child), 
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and assumes the mother continues to breast-feed.1  These regimens were 
chosen because they are easy to administer, and hence have distinct 
advantages in a resource-constrained environment. 
 
 
Government Policy Towards Preventing 
MTCT in South Africa 
 
The history of the AIDS pandemic, and the failure of the apartheid and 
post-apartheid South African governments to respond adequately, have 
been well documented (see, for example, Crewe, 1992; Marais, 2000;  
Whiteside and Sunter, 2000; van der Vliet, 2001).  This literature tells a 
demoralising story about how AIDS policy was overshadowed by 
competing political priorities, undermined by institutional inadequacies and 
insufficient funding, and plagued by high-level scandals.  Once President 
Mbeki raised concerns about the causal relationship between HIV and 
AIDS, South Africa’s AIDS policies were undermined still further.  His 
subsequent inclusion of ‘AIDS dissidents’ like Peter Duesberg and David 
Rasnick (who questioned the efficacy of anti-retroviral treatments and the 
validity of AIDS tests) on his ‘Presidential International Panel of Scientists 
on HIV/AIDS in Africa’ – almost certainly slowed down the development 
of a coherent policy response to the AIDS crisis.    
By the late 1990s, there was a wealth of evidence from developed 
and developing countries that treating pregnant women with a short course 
of anti-retrovirals could reduce MTCT dramatically.  South African 
medical research subsequently came to similar findings (see, for example,  
Söderland et al, 1999; McIntyre and Gray, 1999; Wilkinson et al, 2000).  
However, all the recommended treatment regimes entailed the use of HIV 
                                                           
1 Where substitute feeding is used rather than breast-feeding, MTCT can be reduced 
by about 50% (see Farley et al, 2000; Wood, 2001: 11). However the relative 
advantages of substitute feeding over breast-feeding for reducing MTCT in 
developing countries have yet to be established conclusively.  Indications are that an 
exclusive breast-feeding regime followed by abrupt weaning may be more effective 
than the mixed-feeding regimes typically followed in breast-feeding populations 
(Wood, 2001: 11-12). And, given that substitute feeding is associated with higher 
infant mortality, the life-saving properties of formula-feeding will be reduced 
accordingly.  After reviewing the available evidence, the WHO Technical 
Consultation team (2000) recommended that where substitute feeding is feasible, 
affordable, sustainable and safe, then breast-feeding should be avoided altogether.  
Otherwise, exclusive breast-feeding is recommended, followed by abrupt weaning.  
The decision should be based on counseling the woman so that she can make an 
informed choice. 
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tests and anti-retrovirals – i.e. the very things the AIDS dissidents were 
opposed to (and which the Presidential AIDS Panel was discussing).   
This posed a problem for the Health Ministry, because to 
implement appropriate treatment regimes whilst the Presidential AIDS 
panel was sitting, could have been construed as a slap in the face for the 
President.  But there was another argument against introducing a 
programme to reduce MTCT – and that was that South Africa could not 
afford it.   
This argument first reared its head when the Health Minister (then 
Nkosazana Zuma) announced in 1998 that anti-retrovirals (especially AZT) 
were too expensive.  Arguments to the effect that the paediatric costs of 
HIV-positive children far exceeded the costs of the intervention (see 
Nattrass, 1998; and McIntyre and Gray, 1999) appeared to have had no 
impact.  Once the price of AZT was slashed by Glaxo-Wellcome, and 
Nevirapine  offered free of charge to South Africa for five years, the Health 
Ministry’s argument lost further credibility.  Nevertheless, government 
officials continued to maintain that the programme was unaffordable.  They 
argued that the costs associated with testing all pregnant women for the 
virus, as well as those of the necessary counselling and provision of infant 
formula (to prevent transmission of HIV through breast-milk), were too 
high (Van der Vliet, 2001: 166-7).  The Health Ministry persisted with this 
line of argument, despite work by economists showing that even after 
making adjustments for these further costs, it was still cost-effective to 
prevent MTCT (see Skordis, 2000). 
The Health Ministry’s intransigence unleashed a storm of protest 
from researchers, AIDS activists and church leaders.  The Western Cape 
provincial government decided to ignore government policy and went 
ahead with pilot projects to provide AZT and free infant formula at two 
clinics in Cape Town.  The Treatment Action Campaign (an NGO 
dedicated to providing affordable treatment for those with HIV/AIDS) 
reviewed the available evidence (summarised in Geffen, 2000) and 
threatened to instigate legal proceedings against the national government.  
In early 2001, the government changed its policy stance and 
announced that selected hospitals would provide free HIV tests to pregnant 
women.  Those who tested positive would be offered a short course of 
Nevirapine and six months’ supply of infant formula in order to reduce the 
chances of MTCT.  This apparent concession, however, was not put into 
practice at the national level, and the decision was referred back to cabinet.  
In July 2001, the Treatment Action Campaign instigated legal proceedings 
against the government to force them to implement a national MTCT 
reduction programme.     
The government is still clearly worried about the costs of a 
national programme to prevent MTCT.  Nono Simelela, Chief Director 
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(HIV/AIDS and STDs) in the Department of Health, argued in the Mail and 
Guardian on 28 July 2000 that those advocating such programmes were 
‘cherry-picking’.  She argued that this was a ‘luxury’ that the Health 
Ministry could not afford as it had to respond to the health needs of all 
South Africans.  In other words, the concern was that money spent on 
preventing MTCT was money lost to other parts of the health sector  
The problem with this argument is that it does not take into 
account that the additional children born HIV-positive as a result of 
government inaction also cost the government money.  Such costs have to 
be taken into account explicitly when evaluating whether the programme is 





The emerging literature on the cost-effectiveness of reducing MTCT in 
South Africa tends to be framed in terms of disability-adjusted-life-years, 
i.e. DALYs  (see, for example, Söderland et al, 1999; Geffen, 2000; 
Wilkinson et al, 2000).  DALYs combine ‘time lived with a disability and 
the time lost due to premature mortality’ (Murray, 1994: 441).  DALYs are 
age-weighted and include a discount factor.2     
The DALY is designed to help policy-makers rank interventions in 
terms of cost-per-DALYs saved.  But how useful is it when it comes to 
practical budgetary allocations?   In the Wilkinson et al (2000) study, the 
cost-per-DALY associated with a programme (using AZT) to prevent 
MTCT was estimated as ranging from $17 (R134) in KwaZulu Natal to $46 
(R369) in the Western Cape, averaging $27 (R213) nationally.  Geffen 
(2000) estimated (using different assumptions about formula-feeding, 
seroprevalence and other variables) that the national cost-per-DALY of an 
AZT regime to reduce MTCT was almost three times higher, at $76 (R606) 
per DALY. 
Whilst such calculations are an interesting first step, they are only 
really meaningful from a policy perspective when placed in the context of a 
range of costs per DALY for different interventions.  These must include 
not only interventions in the health sector, but all other government 
programmes and projects that improve health indicators (e.g. the provision 
of clean water, the removal of environmental hazards, income-generating 
programmes, etc.).   As Anand and Hanson point out,  
                                                           
2  Anand and Hanson (1997) argue that this is one of the least attractive features of 
the DALY and that there are no ethical grounds for the application of such 
discounting factors.  See Murray and Acharya (1997) for a defence of the DALY.  
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‘If mother’s education, or improving water supply and 
sanitation conditions generate bigger ‘bang-for-a-buck’ than 
health interventions, then the health budget should be 
redirected to the ministry of education, or of public utilities.  A 
committed DALY maximiser should in principle be willing to 
give over the entire health budget to other ministries!  
Otherwise, this restricted cost-effectiveness exercise can lead 
to a seriously sub-optimal allocation of resources in the 
improvement of health outcomes’ (1997: 699).      
 
In South Africa’s case, very few DALY calculations have been 
made with regard to government programmes.  Wilkinson et al report two 
other estimates for comparative purposes: an immunisation programme 
ranging from $25-30 per DALY, and a family planning programme at 
$100-150 per DALY (both in 1990 prices).  But what does this mean in 
policy terms?  Does it mean that we should be putting more money into 
reducing MTCT than into family planning?  And, given that immunisation 
appears to be more cost effective than reducing MTCT in the Western 
Cape, should we put money into the former rather than the latter 
programme?   Of course Wilkinson et al would argue vigorously against 
any such interpretation, as there are no doubt many other programmes (such 
as kidney dialysis and heart transplants) which are undoubtedly much less 
cost-effective in terms of cost-per-DALY.  However, until such time as a 
significant number of comparable DALY studies (using similar 
assumptions) have been done, an isolated cost-effectiveness measure (or 
even a small collection of such measures) is of limited policy significance.   
Some South African authors have attempted to get around this 
problem by comparing cost-per-DALY with some kind of objective 
standard of cost-effectiveness.  For example, Söderlund et al (1999) cite the 
1993 World Development Report as suggesting that interventions costing 
less than $100 per life year saved are cost-effective for developing 
countries.  Geffen (2000) uses the same figure as a benchmark to argue that 
reducing MTCT is cost-effective, and hence worth doing.   However, this 
kind of analysis runs counter to the original purpose of the DALY as a tool 
for allocating health resources between competing claims.  It begs the 
question of how many other interventions cost less than $100 per DALY 
and fails to interrogate the problem of using a rough international indicator 
as a benchmark against which to evaluate policies at country-level.  
At most, presenting such cost-effectiveness calculations alongside 
a rough international benchmark provides some kind of indication that the 
cost per (adjusted) life year is in some sense low.   However, in that case, 
one could well ask why not simply calculate the cost per life saved?  In the 
Wilkinson et al study, the cost per life saved was $841, and in the Geffen 
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study it was $1,378.   Such low costs per life saved are perhaps more 
compelling from a policy point of view than the cost-per-DALY 
calculations.     
 
In the absence of any means of ranking the cost-per-DALY in terms 
of the cost-effectiveness of alternative interventions, the existing South 
African studies express total costs of the programme as a percentage of the 
health budget in order to show the relatively limited resource implications of 
the intervention.  Wilkinson et al (2000) report that a national programme to 
reduce MTCT would amount to less than 1% of the national health budget – 
or $0.49 per person living in South Africa.  In his review of the available 
studies, Geffen observes that there is consensus in the South African 
literature that such a programme will not cost more than 3% of the national 
government health budget (2000: 5).    
But while this is more helpful to the process of budgetary 
allocation than a raw cost-per-DALY, it is not sufficient.  In our subsequent 
net-cost calculations, we also show what percentage of the health budget 
would be absorbed by an intervention to reduce MTCT – but we take the 
calculation one step further and compare this with the costs to the health 
budget of not making the intervention.3     
We present a series of best and worst-case calculations of the cost 
of MTCT, and of trying to reduce MTCT by using a short course of AZT 
versus Nevirapine.  Estimates have been taken from primary and secondary 
studies conducted worldwide – with particular emphasis on those studies 
conducted either in South Africa or in a developing world context.     
For each variable used in the model (such as HIV prevalence, the 
estimated number of women who would accept anti-retroviral therapy, etc. 
a range of observed mean values can be found in the literature.  However, 
for the purposes of this paper, only the highest and lowest available figures 
were used to derive the upper- and lower-bound estimates respectively.   
This has the advantage of making explicit the possible range within which 
our estimates could fall.  Mid-point estimates of the key findings are 
provided in the conclusion. 
As regards screening, the tests used to establish the HIV status of 
mothers are assumed to be Rapid tests rather than ELISAs (hence the high 
uptake figures).  As the name suggests, Rapid tests provide the expectant 
mother with a result shortly after the test.  There is no need for her to return 
to the hospital at a future date to obtain her results.   
Unlike other studies, we move beyond the bounds of the health 
budget by including the costs of the child-support grant (allocated through 
                                                           
3 This approach was pioneered in a polemical piece by Nattrass (1998) and refined 
and improved by Skordis (2000) and Skordis and Nattrass (2001). 
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the Department of Welfare) for HIV-positive children.  Although many 
HIV-negative children also benefit from the grant, we have not included 
these costs in the calculation on the grounds that the state can ‘recover’ this 
investment in human capital when the child grows up to be a productive, 
tax-paying adult.  By contrast, the welfare resources devoted to HIV-
positive children over the course of their short lives are what we term  
‘unrecoverable’ – and should be viewed as a form of consumption 
spending.  For this reason, we have included the welfare costs of HIV- 
positive children, but not HIV-negative children.   
 
 
The Baseline Calculation:  How Much Does it 
Cost to do Nothing? 
 
We start off by outlining a baseline cost to the South African government 
of an HIV-positive child.  This is summarized in Table 1.  We assume that 
the average HIV-positive child spends between 11.9 and 12.7 days in 
hospital care during the course of its life (Cotton et al, 1998) and that the 
cost of a high-care hospital bed is $128 per day (WCDH, 1999).   We opted 
to use the cost of a high-care bed in our calculations for two reasons.  
Firstly, HIV-positive children are likely to be placed in high-care beds 
when they are hospitalised due to the nature of the common opportunistic 
infections with which they present.  Secondly, we did not include in our 
calculations the cost of medication to treat these opportunistic infections.  
HIV-positive children commonly present with serious illnesses such as 
pneumonia, tuberculosis, encephalitis, gastroenteritis, diarrhoea, acute 
respiratory tract infections, marasmia and a host of others.  These diseases 
usually require more care than a low cost, general hospital ward can offer.  
Also, they often require relatively expensive testing to confirm the 
diagnosis, and costly medication for treatment.  Unfortunately, reliable 
estimates of these costs are not readily available, and given the wide range 
of common infections, it is impossible to estimate a credible set of ‘typical’ 
medication costs.  By assuming the costs of a high-care bed, we are 
compensating partially for the absence of medication and diagnostic costs 
in our calculations.4   Note that this is the average cost of a bed.  Given that 
South Africa’s hospitals are operating at, or close to, full capacity in all 
urban centres, this is a reasonable costing assumption.   
                                                           
4 Interestingly, this proxy for pediatric costs of AIDS is very close to 
(i.e.15% below) the average cost (adjusted to 1999 prices) reported by 
studies in Tanzania, Zaire and Thailand (reported in Marseille and Kahn 
(1999: 60)). 
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Note also that this baseline costing exercise excludes the private 
costs borne by parents/care-givers in getting the children to hospital and the 
costs associated with staying home from work to care for the child within 
the home environment.  It is thus a severe under-estimate of the broader 




TABLE 1:  THE COST OF A SINGLE CHILD LIVING WITH HIV 
 Upper Bound 
Lower 
Bound 
1.1.   Average life span for an HIV-positive child in 
months (WCDH,1999), (Hussey et al,1998) 60 32 
1.2.   Mean duration of hospital stay for an HIV-positive 
child - in days (Cotton, 1998) 12.7 11.9 
1.3.   Daily cost of a high-care hospital bed (WCDH, 1999) $128 
1.4.   Inpatient costs per child (excluding symptomatic 
treatment) – This is calculated as the mean duration of the 
hospital stay multiplied by the daily cost of a high-care 
hospital bed (1.2. x  1.3.) 
$1,621 $1, 519 
1.5.   Welfare cost for a single child over duration of life 
span  – calculated at R100 per month over the life of the 
HIV-positive child  
$750 $400 
1.6.   Total cost (health and welfare) per HIV-positive 




The welfare contribution listed in Table 1 is the value of the 
means-tested child-support grant available in South Africa.  The model 
assumes that all mothers with HIV-positive children will receive the child-
support grant.  While this may at first appear to be an over-estimate because 
the grant is means tested and not all HIV-positive mothers will qualify for 
it, it is important to note that the women attending antenatal clinics in South 
Africa are skewed towards the lower-income groups.  It is thus likely that 
the vast majority of HIV-positive children will end up receiving a state 
contribution to their welfare.  Furthermore, the model presented here does 
not take into account the administrative costs to the state of means-testing 
 11
and of distributing the grant to eligible mothers.  These costs are 
substantial, and their exclusion from the welfare cost estimate more than 
compensates for any over-estimation introduced by the assumption that all 
HIV-positive children receive the grant.  The welfare cost estimate is thus 
likely to be an under-estimate. 
The potential costs to the state of caring for an HIV-negative child 
(such as foster-care costs for orphaned children) have not been included for 
two reasons. Firstly, although the child’s mother is more likely to die 
shortly after its birth than one born of an HIV-negative mother, we assume 
that an alternative member of the child’s extended family will take 
responsibility for his or her upbringing (as is largely the case at present).  In 
the event that the child does end up in state care, we deem that cost to be 
‘recoverable’ over the course of his or her adult life, and hence do not 
include it as a cost.   
To summarise then, in the case of an HIV-negative child, the 
welfare payment is considered a transfer payment and as such is not 
included in the calculation as a cost.  In the case of an HIV-positive child 
however, it is considered a cost because the child will not live to repay the 
State for the investment in its well-being. 
Table 1 shows that the cost to the state of a single HIV-positive 
child is between $1,919 and $2,371.  The lower-probability estimate 
assumes that a child lives for 32 months, spends an average of 11.9 days in 
a high-care hospital ward and receives a child-support grant each month for 
the duration of his or her life.  The upper-probability estimate assumes that 
the child will live for 60 months, spends an average of 12.7 days in a high-
care hospital ward and receives a child-support grant each month for the 
duration of his or her life.  
The cost of caring for a single HIV-positive child (as outlined in 
Table 1) is the cost of caring for a child over the duration of his or her life.  
Given that South Africa is in the grip of a growing AIDS pandemic, the 
number of HIV-positive children born each year will be at least the same as 
– and probably more than – the previous year.  One can thus regard the 
numbers in Table 1 as a conservative estimate of the annual cost per child 
from the state’s perspective. 
 
 
The estimated number of HIV-positive children 
Projections of the number of pregnant women used in this paper were 
produced using the Metropolitan Life/Doyle ‘Scenario 99’ Model for 
projections of demographic impacts of HIV/AIDS in South Africa (HIV 
Management Services, 1998).  The number of pregnancies quoted is the 
number of live births anticipated for 1998 and is in line with the estimated 
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number of live births published with the antenatal results for 1996, when 
adjusted for the findings of the 1996 census.   
The number of HIV-positive births used in this study is based on 
the findings of the 1998 Antenatal Clinic Study (HIV Management 
Services, 1998).  The study estimated that approximately 27% of the 
pregnant women presenting at antenatal clinics were HIV-positive.  The 
findings of the 1999 Antenatal clinic study were released recently and have 
raised many questions as to the validity of the data, due to reported changes 
in the methodology.  As such, a lower probability of infection (of 19.2%) 
(UNAIDS/WHO, 2000) amongst pregnant women attending antenatal 
clinics has been included as the lower probability observation, while the 
1998 projected infection rate has been retained as an upper-probability 
estimate in Table 2. 
Another widely accepted model for measuring the impact of 
HIV/AIDS in South Africa is the ASSA600 model (Dorrington, 2000; 
ASSA600, 2000).  The projection calculated by this model starts with an 
estimate of the population as at 1/11/1985 and projects forward annually 
from that date.  The number of HIV-positive children projected for the year 
2000 by the ASSA600 model is 67,912 (ASSA600, 2000). 
This figure is very close to the average of the upper- and lower-
probability findings for Scenario 99.  Using the Scenario 99 measure of the 
population as a base, we arrive at an estimated range of between 48,616 and 
86,415 HIV-positive children born each year.  This is an average of 67,516 
HIV-positive children per year, a slightly lower estimate than that yielded 
by the ASSA600 model. 
 
 
Impact on the Budget 
If the higher estimate of the number of HIV-positive children born each 
year (see Table 1) is multiplied by the upper-bound inpatient costs of caring 
for HIV-positive children, then this amounts to $140.1 million – i.e. 3,5% 
of the Health Budget (see Table 2).  If the lower-bound estimates are used, 
then the cost of caring for HIV-positive children amounts to 1,8% of the 
Health Budget.  Adding the (‘unrecoverable’) welfare costs of these 
children inflates the cost to the state to $205 million and $93.4 million for 
the upper- and lower-bound estimates respectively.  This amounts to 0,% 
and 0,% respectively of the total government budget.   
As argued above, one can make an unanswerable case for the 
affordability of an intervention if the costs of not intervening are greater 
than the costs of intervening.    The rest of the paper shows how a short-
course AZT treatment regime (with breast-feeding) and a single-dose 
Nevirapine regime (with breastfeeding) involve less cost to the state than 




TABLE 2:  THE COST OF HIV-POSITIVE CHILDREN 
 Upper Bound 
Lower 
Bound 
2.1 Number of pregnancies which will potentially 
present at antenatal services (1998)  (HIV Management 
Services, 1998) 
1,012,831 
2.2. HIV prevalence among pregnant women (HIV 
Management Services, 1998, UNAIDS/WHO, 2000) 27.0% 19.2% 
2.3.   The number of HIV-positive pregnant women   (2.2 
x  2.1) 273,464 194,464 
2.4.  Perinatal transmission rate: breastfeeding, vaginal 
delivery and no intervention  (Ratcliffe et al, 1998 
(Cotton,1998) 
31.6% 25.0% 
2.5.  Number of HIV-positive babies perinatally infected 
(2.4. x 2.5) 86,415 48,616 
2.6. Inpatient costs per HIV-positive child (from Table 1) $1,621 $1,519 
2.7.   Total inpatient costs for all HIV-positive children





2.8.   Total inpatient costs of all HIV-positive children as 
% of the government’s Health Budget 3,5% 1,8% 
2.9.   Total welfare costs for all HIV-positive children  $64.9 million 
$19.5 
million 
2.10.   Total costs (health and welfare) of all HIV-





2.11.   Total (health and welfare) costs as percentage of 






Before introducing any form of intervention, the HIV status of the potential 
patient needs to be ascertained.  Studies have shown that between 90 and 
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93% of women are likely to consent to an HIV test at an antenatal clinic 
(HIV Management Services, 1998).  As can be seen in Table 3, the cost of 
pre-test counselling and (Rapid) testing all pregnant women who present at 
antenatal clinics, as well as post-test counselling for HIV-positive women, 
will range from $6.9 million to $7 million.5  Of those screened and found to 
be positive, approximately 92.5% are likely to accept anti-retroviral (ARV) 
treatment to prevent MTCT if they are offered it.  This results in between 
235,248 and 161,891 women being enrolled into the ARV programme. 
 
 
TABLE 3: OUTCOME USING AZT INTERVENTION (WITH BREAST-
FEEDING) 
 Upper Bound 
Lower 
Bound 
3.1.   Number of pregnancies which will potentially 
present at antenatal services (from Table 2) 1,012,831 
3.2.    Counselling costs (rule of thumb is 40 minutes 
per patient and 5000 counselling hours needs 3 full-
time counsellors at $6,875 per annum each.  Each 
counsellor sees 2500 people, i.e. $2.8 per person) per 
person 
$2.8 
3.3.   Cost of pre-test counselling (3.1 x. 3.2) $2.8 million 
3.4.   Percentage of these women who are likely to 
accept an HIV test  (HIV Management Services,1998) 93% 90% 
3.5.   Total number of women likely to be tested for 
HIV (3.1 x 3.4)  941,933 911,548 
3.6.   Direct cost of the test per person (WCDH, 1999) $4.5 
3.7.   Total cost of the HIV test (3.5 x 3.6)  $4.2 million 
$4.1 
million 
3.8.  Total cost of pre-test voluntary counselling and 





3.9.  HIV prevalence among pregnant woman (from 
Table 2) 27% 19.20% 
                                                           
5 The information used to estimate these costs came from the Western Cape 
HIV/AIDS Directorate. 
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3.10.   Number of HIV-positive pregnant woman who 
are likely to be identified through screening (3.4 x 3.9) 254,322 175,017 
3.11.  Cost of post-test counselling for HIV+ women 





3.12.  Percentage of above HIV-positive women who 
are likely to accept anti-retroviral treatment (HIV 
Management Services, 1998) 
92.5% 
3.13.   Number of HIV-positive women accepting the 
anti-retroviral (3.10 x 3.12) 235,248 161,891 
3.14.   Cost of Zidovudine (AZT) to mother (given from 
36 weeks and 3 hourly during labour) per patient  
(WCDH, 1999) 
$57.4 $28.7 
3.15.   The cost per child of PCP Prophylaxis (i.e. 
Bactrim syrup at R1.15 per 50 ml from 2 months to 15 
months) (WCDH,1999) 
$3.3 
3.16.   Cost of administering AZT to all of these HIV-
positive women and providing PCP prophylaxis to the 





3.17.   Total direct costs of the intervention to prevent 





3.18.   Perinatal transmission rate amongst HIV-
positive women who accept AZT (and breastfeed)  
(Dabis et al, 1999, Mansergh et al, 1996) 
18% 16.5% 
3.19.   Perinatal transmission rate amongst those 
women who did not accept the AZT (and who 
breastfeed) (Cotton, 1998, Ratcliffe et al, 1998) 
31.6% 25% 
3.20.   Number of HIV-positive children perinatally 
infected by those who accepted ARV (3.18 x 3.13) 42,345 26,712 
3.21.   Number of HIV-positive children perinatally 
infected by those mothers who refused to be tested, and 
those who tested positive but refused the anti-retroviral 
{[(3.1 – 3.5) x 3.9] + (3.10 – 3.13)} x (3.19) 
12,077 8,143 
3.22.   Total number of HIV-positive children born 
during a programme of AZT intervention  (3.20 + 3.21) 54,422 34,855 
3.23.   Calculated cost of inpatient care per HIV-
positive child excluding symptomatic treatment (from 
Table 1). 
$1,621 $1,519 
3.24.   Calculated cost of inpatient care for projected 
number of HIV-positive children (excluding 






3.25.   Total direct costs for the intervention plus the 
inpatient costs of the projected number of HIV-positive 





3.26.   Number of children saved as a result of the 
intervention (2.5 – 3.22)  31,993 13,761 
3.27.   Direct Intervention costs (i.e. screening, 
counselling, cost of AZT and providing PCP 
prophylaxis to the child) per child saved 3.17/3.26 
$687.7 $915.6 
3.28.   Total health costs of doing nothing to prevent 
MTCT of HIV minus total health costs under the AZT 





3.29   Welfare cost for projected number of HIV-





3.30.   Total cost (health and welfare) for the projected 
number of HIV-positive children under an AZT 





3.31.   Total costs (health and welfare) of doing nothing 
to prevent MTCT of HIV minus total costs (health and 







It costs between $29 and $57 to administer Zidovudine (AZT) to 
each mother enrolled in the programme from the 36th week of her 
pregnancy, followed by three-hourly doses during her labour (WCDH, 
1999).  It costs a further $4 to provide PCP Prophylaxis to each infant 
(WCDH,1999).  This results in a total cost of between $5.2 million and 
$14.3 million to treat all the women enrolled in the programme and each of 
their infants.  This naturally assumes that these women will attend the 
clinics prior to the birth and will not present for the first time in advanced 
labour, as this would make screening and administration of the drug 
prohibitive.  Amongst these women in the programme (i.e. those who 
present at the clinic before the onset of labour, accept testing, and if 
positive, accept ARV therapy), the perinatal transmission rate is likely to 
drop from between 25% (Cotton et al, 1998) and 31.6% (Ratcliffe et al, 
1998) to between 18% (Dabis et al, 1999) and 16.5% (Mansergh et al, 
1996). 
The total number of HIV-positive children born during a 
programme of AZT intervention includes not only the HIV-positive 
children of the women within the programme, but also the children born to 
those women who either did not accept the ARV or were not tested at the 
outset.  With AZT intervention, the total number of HIV-positive children 
born is likely to be between 34,855 and 54,422, which is 13,761 and 31,993 
fewer than would have been the case in the absence of the programme to 
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reduce MTCT.  If we consider the direct costs of the intervention (i.e. 
testing, counselling and the cost of the ARV regime) this amounts to 
between $688 and $916 per child saved.   
In order to examine the issue of affordability, we first examine it 
from the point of view of the Health Budget.  Table 3 shows that it costs the 
Health Ministry between $8 million and $30 million more to treat the HIV-
positive children born in the absence of a programme to reduce MTCT than 
it would to fund such a programme (and treat those children born HIV-
positive despite the programme).  When the welfare cost of HIV-positive 
children is included in the calculation, the difference becomes even greater.  
This indicates that it is costing the government between $14 million and 




While the bulk of available research pertains to AZT, recent findings 
regarding Nevirapine suggest that it holds even greater promise for South 
Africa’s fight against HIV/AIDS.  Trials of Nevirapine indicate that the 
drug may be both more effective and cheaper than AZT (McDougal, 1999; 
Marseille and Kahn, 1999; Farley et al, 2000).  The manufacturer has 
offered Nevirapine to the South African government free of charge for five 
years– and this is the assumption used in Table 4, where the calculations in 
Table 4 follow much the same lines as those in the previous table. 
At a programme cost of as little as between $195 and $410 per 
child saved, Nevirapine can save between 19,265 and 43,520 children every 
year.  As the drug comes in  tablet form, an important benefit is that the 
mother can administer the first dose of the drug to herself when she goes 
into labour, hence reducing the strain on clinics and hospitals to a small 
degree.   
Anecdotal evidence has revealed some concerns about women 
who present to clinics only once they are in labour, i.e. too late for the full 
HIV testing process.  Under these circumstances one might consider 
administering Nevirapine in clinics to ‘late presenters,’ without first 
establishing HIV status.  This could possibly be justified if the mother came 
from a higher-risk sector of the population, and was agreeable to taking the 
drug after the ramifications were fully and clearly explained to her.   This 
possibility has not been included in the costing; however, its inclusion 




TABLE 4: OUTCOME USING NEVIRAPINE INTERVENTION (WITH 
BREAST-FEEDING) 
 Upper Bound 
Lower 
Bound 
4.1.   Direct cost of testing and counselling pregnant women 





4.2.   Cost of NVP for all these HIV-positive women 
(according to recent media reports)  R 0.00 R 0.00 
4.3.   Cost of the PCP prophylaxis to the child  
(WCDH,1999)   





4.4.   Perinatal transmission rate amongst those women who 
accepted NVP (with breastfeeding and vaginal delivery) 
(MacDougall, 1999) 
13.1% 13.1% 
4.5.   Perinatal transmission rate amongst those women who 
do not receive the antiretroviral (with  breastfeeding, vaginal 
delivery and no intervention (from Table 3) 
31.6% 25% 
4.6.   Number of HIV-positive children perinatally infected 
by those who did accept the antiretroviral (4.4 x  3.13) 30,818 21,208 
4.7.   Number of HIV-positive children perinatally infected 
by those mothers who did not accept the antiretroviral or 
who were not tested at the outset (and did not formula feed 
their babies) (from Table 3) 
12,077 8,143 
4.8.   Total number of HIV-positive children born during a 
programme of NVP intervention  
          (4.6 + 4.7)  
42,895 29,351 
4.9.   Calculated cost of inpatient care per child (not 
including symptomatic treatment)  (from Table 1) $1,621 $1,519 
4.10.   Calculated cost of inpatient care for projected number 
of HIV-positive children (not including symptomatic 





4.11.   Total direct costs to the health budget of the 





4.12.   Total health costs of the intervention to prevent 
MTCT of HIV plus the inpatient costs of those children born 





4.13.   Number of children saved (2.5 – 4.8)  43,520 19,265 
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4.14.   Direct intervention costs (i.e. screening, counselling, 
cost of PCP prophylaxis) per child saved (4.11/4.13) $195.3 $410.1 
4.15.   Total health costs of doing nothing to prevent MTCT 





4.16.   Welfare cost for projected number of HIV-positive 
children over duration of life span – calculated at R100 per 





4.17.   Total cost (health and welfare) per annum for the 
projected number of HIV-positive children under an NVP 





4.18.   Total costs (health and welfare) of doing nothing to 
prevent MTCT of HIV minus total costs (health and welfare) 








There are concerns about women developing resistance to 
Nevirapine as a result of taking the drug during labour.  However, after 
reviewing the available evidence, Farley et al conclude that the efficacy of 
Nevirapine in subsequent pregnancies is unlikely to be affected, that the 
transmission of the resistant virus to sexual partners is unlikely, and that the 
course of the mother’s HIV infection would probably not be affected (2000: 
4-5).  Drug resistance is a chronic problem for all HIV/AIDS interventions.  
Those women who develop a long-standing resistance to Nevirapine, and 
who are subsequently are able to access chronic treatment programmes to 
manage their own HIV infection, will have to use a different drug regimen.  
However, as generalized access to ARV medication for adults is not yet on 





We have argued that South Africa cannot afford to do nothing to combat 
MTCT of HIV.  Short of denying HIV-positive children any access to 
healthcare (which would be unconstitutional), the cost of one HIV-positive 
child in terms of basic hospital costs and ‘unrecoverable’ welfare spending 
is substantially greater than the interventions discussed above.  In addition, 
one should remember that this cost per HIV-positive child is a gross under-
estimate as it includes no medicines for treating opportunistic infections, 
none of the economic costs of a parent or guardian staying home from work 
to care for a sick child, and none of the transport costs of getting the sick 
child to medical care.     
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TABLE 5: OVERVIEW OF ALL INTERVENTIONS WITH MID-POINT 
ESTIMATES 














5.1.  Direct costs 















5.2.   Lives saved 31,993 13,761 22,877 43,520 19,265 31,393 
5.3.   Cost of the 
MTCT reduction 
programme per 
saved child  
$687.7 $915.6 $801.7 $195.3 $410.1 $302.7 
5.4.   Cost of the 
MTCT reduction 
programme per 
DALY (5.3/32)  
$21.5 $28.6 $25.1 $6.1 $12.8 $9.5 
5.5.   Total 
amount saved by 
the Health 
Budget as a 
result of the 
programme to 
















5.6.   Amount 
saved by the 
Health and 
Welfare Budgets 
as a result of the 
programme to 
















5.7.   Amount 
saved by the 
Health and 
Welfare Budgets 
as a result of the 
programme to 
reduce MTCT of 
HIV per DALY 
(5.6 / (5.2 x 32) 




Table 5 summarizes some of the key results with regard to 
affordability.  Although the AZT regimen saves the most lives, the 
Nevirapine regimen has the lowest cost per life saved and has the additional 
advantage of being simple to administer.  In Table 5, we convert this into a 
rough cost-per-DALY measure by multiplying the number of lives saved by 
32, i.e. the DALY estimate used by Wilkinson et al, 2000.  However, this 
tells us nothing more, in terms of policy implications, than what we already 
knew from the simple cost-per-life-saved calculation.   
 
As we argued in the introduction, the cost-per-DALY measure of 
cost-effectiveness is limited in that it requires a large range of other cost-
per-DALY measures in order to be of policy relevance.   Our  approach to 
the issue of affordability does not suffer such drawbacks: if the costs of not 
intervening are higher than the costs of intervening, then the intervention is 
clearly affordable.  We have argued that this is the case with regard to the 
two MTCT reduction programmes discussed in the paper. 
Consider the estimates in Table 5.  We show that it would save the 
Health Budget between $8 million and $29.9 million (in the case of the 
AZT regimen) and between $21.4 million and $62.1 million (in the case of 
the Nevirapine regimen) if the government intervened to reduce MTCT.  
This is because the costs of in-patient care associated with the higher 
number of HIV-positive children born in the absence of a programme to 
reduce MTCT more than compensates for the costs of the intervention, and 
costs of in-patient care, for those HIV-positive children born despite the 
programme.   If we include the ‘unrecoverable’ welfare costs of those 
children who are born HIV-positive on both sides of the equation, then the 
Health and Welfare Departments together would save between $14 million 
and $54 million (AZT regimen) and between $29.2 million and $94.8 
million (Nevirapine regimen) if a programme to reduce MTCT was 
introduced.  
Note that if we were again to cast this particular cost-effectiveness 
calculation in a DALY framework, we would take the unusual step of 
dividing the amount the government saves through the intervention (rather 
than the cost of the intervention) by the number of DALYs saved by the 
intervention.  Thus, as Table 5 shows, the government would be saving 
between $21.5 and $28.6 (AZT regimen) and between $6.1 and $12.8 
(Nevirapine regimen) for every DALY saved by a programme to reduce 
MTCT if health costs alone are considered, and between $31.8 and $52.8 
(AZT regimen) and $47.4 and $68.1 (Nevirapine regimen) if health and 
welfare costs are considered! 
 One could, of course, argue that we have over-estimated the costs 
of HIV-positive children to the state because we have not taken into 
account the fact that as the AIDS pandemic approaches its peak, over-
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stretched hospitals will ration health care away from HIV-positive children 
and adults.  Indeed, there is evidence that at least one hospital has already 
ruled that HIV-positive children are allowed only one hospital stay, and 
must otherwise be treated as out-patients (reported in Nattrass, 2001).  
However, even if we cut the health cost of an HIV-positive child to one 
hospital visit ($127) and add a rough (low) estimate for the cost of out-
patient visits (say $50), and then assume further that the child dies earlier as 
a result (say at 24 months rather than the lower-bound 32 month estimate – 
thus costing the government only $300 in welfare grants), the total cost 
($477) still exceeds the upper-bound cost-per-child saved of implementing 
a Nevirapine MTCT reduction programme (i.e. $410.1). 
At this point the argument enters deep ethical territory.  After all, 
if the government ruled that all babies born to HIV-positive mothers should 
be strangled at birth, they would end up costing the government nothing.  
Under such circumstances, our argument for the affordability of a MTCT 
reduction programme would clearly no longer hold.  Fortunately no one is 
arguing this case in South Africa and it is illegal to discriminate against 
anyone on the grounds of  his or her HIV status.  
The power of the argument we make here is simply this:  unless 
the government is planning to deny HIV-positive children access to basic 
health care and welfare payments, it will save money by implementing a 
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